Your browser is no longer supported. Please, upgrade your browser.
Settings
SNDX Syndax Pharmaceuticals, Inc. daily Stock Chart
SNDX [NASD]
Syndax Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.01 Insider Own- Shs Outstand23.97M Perf Week10.21%
Market Cap173.30M Forward P/E- EPS next Y-3.37 Insider Trans- Shs Float23.36M Perf Month4.33%
Income-72.00M PEG- EPS next Q-0.76 Inst Own75.20% Short Float7.94% Perf Quarter-3.47%
Sales2.30M P/S75.35 EPS this Y10.10% Inst Trans-0.04% Short Ratio5.73 Perf Half Y-34.45%
Book/sh2.85 P/B2.54 EPS next Y-9.80% ROA-59.10% Target Price27.25 Perf Year-40.00%
Cash/sh4.16 P/C1.74 EPS next 5Y- ROE-80.30% 52W Range6.10 - 15.20 Perf YTD-17.47%
Dividend- P/FCF- EPS past 5Y-38.40% ROI-59.40% 52W High-53.06% Beta-
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin- 52W Low16.96% ATR0.55
Employees44 Current Ratio5.40 Sales Q/Q33.30% Oper. Margin- RSI (14)49.59 Volatility6.59% 9.06%
OptionableYes Debt/Eq0.00 EPS Q/Q-6.40% Profit Margin- Rel Volume0.79 Prev Close7.23
ShortableYes LT Debt/Eq0.00 EarningsNov 06 AMC Payout- Avg Volume323.44K Price7.13
Recom1.70 SMA20-1.74% SMA50-1.09% SMA200-21.11% Volume156,211 Change-1.32%
Jan-05-18Initiated B. Riley FBR, Inc. Buy $40
Mar-16-17Initiated FBR & Co. Outperform $27
Mar-02-17Initiated Instinet Buy $27
Oct-07-16Initiated Guggenheim Buy
Mar-28-16Initiated Morgan Stanley Overweight $22
Mar-28-16Initiated JMP Securities Mkt Outperform $28
Mar-28-16Initiated Citigroup Buy $24
Oct-18-18 08:35AM  Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive Networks, KalVista Pharmaceuticals, and Adtalem Global Education New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Sep-26-18 07:00AM  Syndax to Present at the 2018 Cantor Global Healthcare Conference PR Newswire
Sep-25-18 04:05PM  Syndax Announces Changes to its Board of Directors PR Newswire
08:51AM  Do Options Traders Know Something About Syndax (SNDX) Stock We Don't? Zacks
08:30AM  The Daily Biotech Pulse: Syndax Lung Cancer Trial Disappoints, Gemphire To Trim Workforce, Opiant's Offering Benzinga
Sep-24-18 04:05PM  Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer PR Newswire +6.79%
Sep-12-18 03:54PM  Are Syndax Pharmaceuticals Incs (NASDAQ:SNDX) Interest Costs Too High? Simply Wall St. -9.79%
Sep-11-18 12:27PM  Edited Transcript of SNDX earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Sep-05-18 05:00PM  Syndax to Present at the International Association for the Study of Lung Cancer 19th World Conference on Lung Cancer PR Newswire
Aug-28-18 07:00AM  Syndax Announces Participation at Three Upcoming Investor Conferences PR Newswire
Aug-27-18 08:15AM  New Research: Key Drivers of Growth for REGENXBIO, Syndax Pharmaceuticals, Rowan Companies, CTS, Basic Energy Services, and Impinj Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-07-18 06:20PM  Syndax Pharmaceuticals (SNDX) Reports Q2 Loss Zacks
05:15PM  Syndax: 2Q Earnings Snapshot Associated Press
04:05PM  Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Clinical and Business Update PR Newswire
02:30PM  Syndax Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Jul-31-18 07:00AM  Syndax to Announce Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018 PR Newswire
Jun-22-18 07:35AM  Research Report Identifies NetScout, Waterstone Financial, Lindblad Expeditions, Syndax Pharmaceuticals, Hospitality Properties Trust, and NewMarket with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
May-30-18 04:05PM  Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration PR Newswire
07:00AM  Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences PR Newswire
May-21-18 07:30AM  Blog Exposure - Syndax Pharma Shares Results of Phase-2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA ACCESSWIRE
May-17-18 07:00AM  Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) PR Newswire -22.57%
May-16-18 08:02AM  Edited Transcript of SNDX earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 06:16PM  Syndax: 1Q Earnings Snapshot Associated Press
04:05PM  Syndax Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Clinical and Business Update PR Newswire
May-03-18 07:40AM  Detailed Research: Economic Perspectives on Park-Ohio, WageWorks, Parker-Hannifin, Sturm, Ruger, Syndax Pharmaceuticals, and Fastenal What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-01-18 07:00AM  Syndax to Announce First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 8, 2018 PR Newswire
Apr-25-18 04:05PM  Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting PR Newswire
Apr-13-18 07:00AM  Syndax to Present at the 2018 American Association for Cancer Research Annual Meeting PR Newswire
Mar-19-18 08:00AM  Analysis: Positioning to Benefit within ICF International, Invitae, Encore Wire, Alexandria Real Estate Equities, Syndax Pharmaceuticals, and Vical Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-17-18 08:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Mar-15-18 08:10AM  Todays Research Reports on Trending Tickers: CRISPR Therapeutics and Syndax Pharmaceuticals ACCESSWIRE -8.10%
Mar-14-18 03:43PM  Here's Why Syndax Pharmaceuticals Is Soaring Today Motley Fool +28.36%
Mar-06-18 06:26PM  Edited Transcript of SNDX earnings conference call or presentation 5-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-05-18 04:37PM  Syndax reports 4Q loss Associated Press
04:05PM  Syndax Pharmaceuticals Reports Fourth Quarter 2017 Financial Results and Provides Clinical and Business Update PR Newswire
12:00PM  Syndax Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
07:00AM  Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences PR Newswire
06:19AM  Syndax Pharmaceuticals Inc (NASDAQ:SNDX): Does The -16.61% Earnings Decline Make It An Underperformer? Simply Wall St.
Feb-26-18 07:00AM  Syndax to Announce Fourth Quarter and Year-end 2017 Financial Results and Host Conference Call and Webcast on March 5, 2018 PR Newswire
Feb-22-18 07:00AM  Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting PR Newswire
Feb-01-18 07:00AM  Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca PR Newswire
Jan-18-18 09:45AM  4 of the Best Stocks to Buy on Earnings Acceleration InvestorPlace
09:25AM  3 Top-Ranked Drug Stocks That Are Broker Favorites InvestorPlace
09:20AM  Zacks.com highlights: Dollar Tree, Syndax Pharmaceuticals, Financial Partners and Union Bankshares Zacks
Jan-16-18 08:41AM  Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter? Zacks
Jan-10-18 07:00AM  Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer PR Newswire
Jan-09-18 08:30AM  Investor Expectations to Drive Momentum within Cutera, Matrix Service, PRA Group, Materion, Second Sight Medical Products, and Syndax Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire +5.35%
Dec-28-17 12:41PM  ETFs with exposure to Syndax Pharmaceuticals, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:37AM  Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-13-17 01:58PM  ETFs with exposure to Syndax Pharmaceuticals, Inc. : December 13, 2017 Capital Cube
Nov-13-17 02:42PM  Edited Transcript of SNDX earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents -15.92%
Nov-11-17 03:00PM  Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting PR Newswire
Nov-07-17 06:24PM  Syndax reports 3Q loss Associated Press
04:05PM  Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update PR Newswire
12:10PM  Syndax Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
08:00AM  Syndax to Present at the SITC 32nd Annual Scientific Meeting PR Newswire
Oct-31-17 07:00AM  Syndax to Announce Third Quarter 2017 Financial Results and Host Conference Call and Webcast on November 7, 2017 PR Newswire
Oct-19-17 07:10AM  Featured Company News - Syndax Pharma Signs Worldwide License Agreement for Allergan's Portfolio of Menin-MLL Inhibitors ACCESSWIRE
Oct-17-17 07:01AM  Syndax Announces $25 Million Registered Direct Offering of Common Stock PR Newswire
07:00AM  Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors PR Newswire
Oct-05-17 07:00AM  Syndax Announces Dosing of First Patient in Pivotal Trial of Entinostat for the Treatment of Advanced or Recurrent Breast Cancer in Japan by Partner Kyowa Hakko Kirin PR Newswire
Sep-20-17 07:00AM  Syndax Pharmaceuticals Announces Updated Presentation Time at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-12-17 06:02AM  The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals Zacks -6.63%
Aug-30-17 07:00AM  Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences PR Newswire
Aug-24-17 10:49AM  Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube +5.94%
Aug-14-17 02:25PM  Edited Transcript of SNDX earnings conference call or presentation 10-Aug-17 8:30pm GMT Thomson Reuters StreetEvents +9.17%
Aug-10-17 09:43PM  Syndax reports 2Q loss Associated Press
04:05PM  Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update PR Newswire
01:00PM  Investor Network: Syndax Pharmaceuticals Inc to Host Earnings Call ACCESSWIRE
Aug-09-17 08:39AM  Why Earnings Season Could Be Great for Syndax Pharmaceuticals (SNDX) Zacks
Aug-03-17 07:00AM  Syndax to Announce Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 10, 2017 PR Newswire
Jul-26-17 08:08AM  3 Under-the-Radar Stocks in the Healthcare Sector Motley Fool
Jul-11-17 04:05PM  Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy PR Newswire
Jun-21-17 08:30AM  Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance Business Wire
Jun-19-17 04:46PM  Edited Transcript of SNDX earnings conference call or presentation 8-May-17 8:30pm GMT Thomson Reuters StreetEvents +7.05%
Jun-16-17 04:19PM  ETFs with exposure to Syndax Pharmaceuticals, Inc. : June 16, 2017 Capital Cube
Jun-05-17 02:47PM  ETFs with exposure to Syndax Pharmaceuticals, Inc. : June 5, 2017 Capital Cube -7.70%
Jun-02-17 09:42AM  Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-24-17 07:22PM  Syndax Prices Public Offering of Common Stock GlobeNewswire -5.32%
May-23-17 04:48PM  Syndax Announces Proposed Public Offering of Common Stock GlobeNewswire
May-17-17 05:07PM  Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma GlobeNewswire +44.62%
10:35AM  Why Syndax Shares Are Rallying 24/7 Wall St.
May-16-17 05:26PM  Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies GlobeNewswire
May-15-17 07:00AM  Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference GlobeNewswire
May-08-17 07:45PM  Edited Transcript of SNDX earnings conference call or presentation 8-May-17 8:30pm GMT Thomson Reuters StreetEvents
04:27PM  Syndax reports 1Q loss Associated Press
04:05PM  Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update GlobeNewswire
11:10AM  Investor Network: Syndax Pharmaceuticals Inc. to Host Earnings Call Accesswire
May-01-17 07:00AM  Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017 GlobeNewswire
Apr-27-17 07:00AM  Syndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Colorectal Cancer GlobeNewswire
Apr-20-17 04:05PM  Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting GlobeNewswire
Apr-04-17 07:00AM  Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors GlobeNewswire
07:00AM  Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors
Mar-29-17 07:00AM  Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-18-17 01:04PM  SYNDAX PHARMACEUTICALS INC Financials
Mar-16-17 07:09AM  Coverage initiated on Syndax Pharmaceuticals by FBR & Co.
Mar-15-17 01:58PM  Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Capital Cube
01:58PM  Syndax Pharmaceuticals, Inc. :SNDX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
Mar-14-17 02:09PM  SYNDAX PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Mar-03-17 12:21AM  Edited Transcript of SNDX earnings conference call or presentation 2-Mar-17 9:30pm GMT Thomson Reuters StreetEvents
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.